中美双批!恒赛生物KSD-101注射液临床开发进程再提速
6872026年3月9日,恒赛生物KSD-101注射液获中国国家药监局药品审评中心(CDE)临床试验默示许可(IND获批),适应症为“经标准治疗无效的EBV相关血液肿瘤”,标志着中国首个获得美国FDA IND批件、中国首个获得FDA快速通道资格(FTD)认定的原创树突细胞疫苗(DC疫...
View detailsSearch the whole station
The snake offered a new chapter, and the elites went to the spring banquet together. At the time when the snake is coiled up and everything is new, all the staff of Hengsai Bio-technology gathered together and held the 2025 Annual Meeting and Annual Summarization Activity in Zhoushan, Zhejiang Province. The team of Hengsai traveled on the waves, refined tacit understanding with collaboration, and coalesced consensus with laughter, and drew the prelude of the New Year together in the blue sea and golden sand.

Breaking through ten thousand hectares of waves, the team went on a journey to the blue sea. Cruising, experiencing the catch, the frequent reports of harvesting the nets, and the picture of the fish jumping in the cabin are just like the epitome of the team's struggle to ride the waves and reap the fruits of success.

Under the setting sun, the tug-of-war field shouting, rope ends of the tug-of-war is the tenacity of all the people; you draw me to guess the fun, between the strokes of the flow is the tacit understanding of the heart; the long rope flying in the leaping figure, like a hundred barges competing for the flow of the enterprising posture. Sweat and laughter intertwined, cohesion into an unstoppable centripetal force.
As the night falls, the fireworks pour down like the Milky Way, and the bright light illuminates every face looking up. Hengsai Bio is willing to be a light chaser in the dark night, with today's fervor as a prelude to become tomorrow's industry stars, so that the team's light is like a prairie fire, reflecting the future journey!


The fruitful results of pectinization and rain, and the continuation of the chapter of China. Dr. Liu Huining, Founder and CEO of Hengsai Biotechnology, delivered a wonderful speech at the year-end summary meeting, reviewing the fruitful results of Hengsai Biotechnology in the past year, affirming the dedication of every team member, and looking forward to the infinite possibilities of dendritic cell vaccines in the future.

The co-founder, Mr. Cheng Xiangguo, takes the company's values as a link to nourish the team's identity and build an evergreen foundation. The concept of gathering the spirit of all rivers, stimulating the potential of cells, empowering doctors, creating a team of grandeur is deeply rooted in people's hearts.

Hengsai Biological R&D Department, Quality Department, Quality Inspection Department, Production Department, Clinical Department, Administration Department, Information Department, Business Department and other persons in charge of the past year's work are summarized in detail, the data is like a pearly gleam on the plate, and the project seems to be like a brocade spread.
Those who take the lead will win the first prize; those who are dedicated to their work will be honored in the end. At the award ceremony, the excellent staff won the high light moment belonging to them with their professional ability and outstanding performance. Hengsai Bio-technology can not be separated from the struggle of every member today, and taking the example as a mirror, we will continue to work hand in hand in the new year to create a brilliant future! We are looking forward to more members standing on the stage of glory and growing together with Hengsai Bio!

With faith as a sail, break the waves of the old age;
Use collaboration as an oar to start a new journey;
Use innovation as an anchor to set the standard of the industry!
May Hengsai Bio be like a star that starts a prairie fire and glows in the sky.
With innovation as the wing to write another chapter;
May the dreamers be like the spring tide that breaks through a thousand pounds.
Climbing to the top by the power of one mind!
END
2026年3月9日,恒赛生物KSD-101注射液获中国国家药监局药品审评中心(CDE)临床试验默示许可(IND获批),适应症为“经标准治疗无效的EBV相关血液肿瘤”,标志着中国首个获得美国FDA IND批件、中国首个获得FDA快速通道资格(FTD)认定的原创树突细胞疫苗(DC疫...
View detailsHengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
View details1. PURPOSE This document describes KOUSAI´s position, and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. This document describes KOUSAI´s position and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. SCOPE We cover ...
View detailsOn October 21st, 2025, the Cancer Hospital of Fudan University held a kick-off meeting for the project "KSD-301 in combination with AG regimen (Gemcitabine, Albumin Paclitaxel) for the treatment of locally advanced unresectable pancreatic cancer". The project is led by Prof. Xianjun Yu, President of the Affiliated Cancer Hospital of Fudan University and Director of the Institute of Pancreatic Tumor Research of Shanghai and Fudan University, as the principal investigator, and the investigational drug KSD-301 is Hengsai's...
View details